EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS <12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY. (4th December 2020)
- Record Type:
- Journal Article
- Title:
- EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS <12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY. (4th December 2020)
- Main Title:
- EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS <12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY
- Authors:
- Obrecht, Denise
Mynarek, Martin
von Hoff, Katja
Witt, Hendrik
Pajtler, Kristian W
Juhnke, B Ole
Warmuth-Metz, Monika
Bison, Brigitte
Kortmann, Rolf-Dieter
Timmermann, Beate
Pfister, Stefan M
Sahm, Felix
Sturm, Dominik
von Deimling, Andreas
Schüller, Ulrich
Pietsch, Torsten
Benesch, Martin
Gerber, Nicolas U
Rutkowski, Stefan - Abstract:
- Abstract: BACKGROUND: For infant ependymoma (EP), decision for radiotherapy during first-line therapy is a dilemma. We analyzed therapy outcomes of EP patients younger than 12 months at diagnosis according to molecular subgroup. PATIENTS AND METHODS: Between 2001 and 2017, 30 patients with histological diagnosis of intracranial EP <12 months at diagnosis with DNA-methylation profiling available were registered in HIT-MED-studies/-registries. RESULTS: In 3/30, DNA methylation-based CNS tumor classification suggested a diagnosis other than EP or could not be assigned to a reference class. Of the remaining 27 tumors, 16 were classified as PF-A, 8 as RELA -fusion positive and 3 as YAP -fusion positive. Median age at diagnosis was 0.73 (0.30–0.99) years. After a median follow-up time of 5.36 (0.20–12.90) years, 59.3% experienced progressive disease (PD). 5y-PFS and -OS for the whole cohort were 38.2% and 73.1%. RELA - and YAP -fusion positive EP had significantly better OS than PF-A (5y-OS for PF-A: 55.9%; RELA 100%; YAP 100%; p=0.023). PFS was not significantly different. All but one patient with relapsed PF-A died despite multimodal salvage strategies. In contrast, patients with relapsing RELA - and YAP -fusion positive EP (n=5), survived with a combination of re-surgery and first or second local radiotherapy. CONCLUSION: In this cohort of infants <12 months, patients with PF-A had a significantly inferior OS compared to patients with RELA - and YAP -fusion positive EP. SalvageAbstract: BACKGROUND: For infant ependymoma (EP), decision for radiotherapy during first-line therapy is a dilemma. We analyzed therapy outcomes of EP patients younger than 12 months at diagnosis according to molecular subgroup. PATIENTS AND METHODS: Between 2001 and 2017, 30 patients with histological diagnosis of intracranial EP <12 months at diagnosis with DNA-methylation profiling available were registered in HIT-MED-studies/-registries. RESULTS: In 3/30, DNA methylation-based CNS tumor classification suggested a diagnosis other than EP or could not be assigned to a reference class. Of the remaining 27 tumors, 16 were classified as PF-A, 8 as RELA -fusion positive and 3 as YAP -fusion positive. Median age at diagnosis was 0.73 (0.30–0.99) years. After a median follow-up time of 5.36 (0.20–12.90) years, 59.3% experienced progressive disease (PD). 5y-PFS and -OS for the whole cohort were 38.2% and 73.1%. RELA - and YAP -fusion positive EP had significantly better OS than PF-A (5y-OS for PF-A: 55.9%; RELA 100%; YAP 100%; p=0.023). PFS was not significantly different. All but one patient with relapsed PF-A died despite multimodal salvage strategies. In contrast, patients with relapsing RELA - and YAP -fusion positive EP (n=5), survived with a combination of re-surgery and first or second local radiotherapy. CONCLUSION: In this cohort of infants <12 months, patients with PF-A had a significantly inferior OS compared to patients with RELA - and YAP -fusion positive EP. Salvage therapy was ineffective for patients with PF-A, whereas patients with can RELA - and YAP -fusion positive EP can be long-term survivors after PD. Therefore, subgroups-specific therapy should be discussed. … (more)
- Is Part Of:
- Neuro-oncology. Volume 22(2020)Supplement 3
- Journal:
- Neuro-oncology
- Issue:
- Volume 22(2020)Supplement 3
- Issue Display:
- Volume 22, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 22
- Issue:
- 3
- Issue Sort Value:
- 2020-0022-0003-0000
- Page Start:
- iii309
- Page End:
- iii309
- Publication Date:
- 2020-12-04
- Subjects:
- Brain Neoplasms -- Periodicals
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481 - Journal URLs:
- http://neuro-oncology.dukejournals.org/ ↗
http://neuro-oncology.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/content?genre=journal&issn=1522-8517 ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/neuonc/noaa222.149 ↗
- Languages:
- English
- ISSNs:
- 1522-8517
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.288000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15438.xml